title: Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
abstract: Ovarian cancer is the fifth most common malignancy with approximately 22,000 newly diagnosed cases each year in the USA. Standard of care after cytoreductive surgery is the application of carboplatin and paclitaxel. The newly developed anti-idiotypic monoclonal antibody abagovomab demonstrated promising results in Phase I/II trials. This new type of drug is currently being tested in a Phase II/III trial in ovarian cancer patients with a complete response after standard first-line chemotherapy. Activating the cancer hosts immune system is a new strategy that is worth being pursued in the fight against ovarian cancer.
authors.affiliation: Department of Gynecology and Obstetrics, University Clinic Schleswig-Holstein, Campus Kiel, Michaelisstrasse 16, 24105 Kiel, Germany. dbauerschlag@hotmail.com
authors.forename: Dirk O
authors.initials: DO
authors.lastname: Bauerschlag
authors.forename: Christian
authors.initials: C
authors.lastname: Schem
authors.forename: Klaus
authors.initials: K
authors.lastname: Baumann
authors.forename: Philip
authors.initials: P
authors.lastname: Harter
authors.forename: Felix
authors.initials: F
authors.lastname: Hilpert
authors.forename: Uwe
authors.initials: U
authors.lastname: Wagner
authors.forename: Andreas
authors.initials: A
authors.lastname: du Bois
authors.forename: Jakobus
authors.initials: J
authors.lastname: Pfisterer
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; C518318:abagovomab